Lannett Company, Inc., a generic pharmaceutical manufacturer, and Spectrum Pharmaceuticals, Inc., have announced an agreement for the manufacturing, supply, distribution and marketing of Ciprofloxacin tablets.
Arthur Bedrosian, Lannett’s President, said, “We are excited about the opportunity to work with Spectrum on this venture. With a talented scientific staff, Spectrum has an excellent future in the pharmaceutical industry. We believe that we can assist Spectrum with the strong relationships that we have with our customers.”
Under the terms of the agreement, Spectrum, through its NeoJB, LLC subsidiary, will provide Ciprofloxacin tablets exclusively for Lannett.
Lannett will market and distribute the product exclusively for Spectrum in the United States.
Spectrum filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration (FDA) in cooperation with their joint venture partner J.B. Chemicals & Pharmaceuticals.
Following approval of the ANDA, Lannett will launch its distribution of the product to its growing base of customers, including wholesale distributors, generic drug distributors, mail-order wholesalers, warehousing chains, retail chains and other pharmaceutical companies.